Omega-3 fatty acid supplements do not reduce CV risk
Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks Meta-analysis of 10 Trials Involving 77917 IndividualsLiterature - Aung T, Halsey J, Kromhout D, et al - JAMA Cardiol 2018; published online ahead of print
- During a mean follow-up of 4.4 years (1.0 – 6.2), omega-3FA supplementation (226-1800 mg/day EPA and 0-1700 mg/day) was not significantly associated with the RRs for: any CHD event (RR: 0.96; 95%CI: 0.90-1.01; P=0.12), CHD death (RR: 0.93; 99%CI: 0.83-1.03; P=0.05), non-fatal MI (RR: 0.97; 99%CI: 0.87-1.08; P=0.40), major vascular events (RR: 0.97; 95%CI: 0.93–1.01; P=0.10), stroke (RR: 1.03; 95%CI: 0.93-1.13; P=0.56), revascularization events (RR: 0.99; 95%CI: 0.94-1.04; P=0.61), all-cause mortality (RR: 0.96; 95%CI: 0.92-1.01; P=0.16).
- No significant heterogeneity was observed between the results of individual trials for non-fatal MI, CHD death, any CHD event, or all major vascular events.
- The results were similar after adjustment for multiple testing, and in pre-specified subgroups, including those defined by gender, history of CHD, history of diabetes, pretreatment levels of total cholesterol, high-density lipoprotein levels, low density lipoprotein levels, triglyceride levels, or prior use of statin therapy.
- There was some evidence of heterogeneity in the associations of omega-3 FAs with major vascular events by age (unadj P=0.02) and by history of stroke (P=0.06).
A large meta-analysis showed that omega-3 FA supplementation is not associated with a reduction in fatal and non-fatal CHD and other major vascular events. These data do not support the recommendation to use of ~1 g/d of omega-3-FA supplements for the prevention of CV events. It will be interesting to see whether higher doses of omega-3 FA (3-4 g/d) may have significant effects on risk of major vascular events.